#United States #Gene Editing #Broad Institute #Jackson Laboratory #Bar Harbor

Introduction

The Jackson Laboratory (JAX), a renowned biomedical research institution, has recently made headlines with its selection for a substantial funding award aimed at revolutionizing the treatment landscape for pediatric epilepsy and rare central nervous system (CNS) disorders. In a collaborative effort alongside the Broad Institute and other partners, this initiative aims to significantly enhance gene editing platforms specifically tailored for these underserved medical areas.

Award Announcement

On July 9, 2026, JAX announced its achievement in obtaining an up to $34.5 million contract from the Advanced Research Projects Agency for Health (ARPA-H), under the purview of the U.S. Department of Health and Human Services. The funding will facilitate the development of the Pediatric Epilepsies Rare CNS Gene Editing Platform (PERC), a groundbreaking project aiming to leverage precision genetic medicine to address challenging pediatric neurological conditions.

Project Objectives

The PERC initiative is set to tackle two severe pediatric conditions: alternating hemiplegia of childhood (AHC) and Dravet syndrome. It will pursue three main objectives:

• - Advancing gene-editing strategies for AHC and Dravet syndrome.
• - Building robust evidence to support the transition to first-in-human clinical studies.
• - Establishing a reproducible platform capable of scaling applications to additional rare neurogenetic disorders.

The project embodies a systematic approach to rare disease research, streamlining processes that traditionally may have started from scratch.

A Call to Action for Rare Disease Treatment

Cathleen (Cat) Lutz, PhD, vice president at JAX, emphasized the urgency of this project: "AHC and Dravet syndrome are incredibly devastating for affected children and their families. Our long-term goal is to create a more seamless integration of disease models, gene editing strategies, and regulatory pathways, accelerating the provision of treatment options to those who need it most."

Addressing Rare Diseases

Rare diseases affect millions globally, with a significant focus on pediatric populations. Notably, around half of identified rare genetic diseases involve the CNS, with 90% of these conditions resulting in severe neurological impacts. Current drug development models aren't well-suited to address the unique challenges posed by rare diseases, particularly due to limited patient populations and the complexities involved in delivering effective treatments to the brain.

Collaborative Efforts

The THRIVE award not only facilitates JAX’s work but also represents a collective response to the conundrum of effective rare disease treatment. The collaboration between JAX, the Broad Institute, and Boston Children's Hospital, along with numerous advocacy and therapeutic development partners, demonstrates a unified approach toward tackling the intricacies of genetic medicine.

Winston Yan, MD, PhD, Co-founder of the Center for Therapeutic Genetics, remarked on the importance of this coalition: "We’re mobilizing critical expertise from various domains, allowing us to develop next-generation precision medicines that effectively address urgent patient needs today and lay groundwork for future applications across additional rare CNS diseases."

A Federal Initiative

This initiative is part of a broader federal strategy aimed at accelerating clinical research and affirming the U.S.'s leadership in medical advancements. With provisions in place to minimize delays in clinical trials and enhance the efficiency of medical studies, ARPA-H's THRIVE program stands at the forefront of this endeavor.

The Jackson Laboratory’s Legacy

Founded in 1929, The Jackson Laboratory is known for its pivotal role in the realm of genetics and genomic medicine. By hosting nearly 3,000 employees and a plethora of facilities across the U.S. and Japan, JAX continues to forge paths in biomedical research, driven by its commitment to enhancing human health through innovative genomics.

Conclusion

The PERC initiative holds the potential to redefine treatment options for children suffering from debilitating neurological conditions through innovative genetic technologies. As work progresses, the JAX-led team aims to not only fulfill immediate patient needs but also to establish a far-reaching methodology for the broader rare disease community, ultimately driving forward the frontiers of precision medicine.